Medicinova (MNOV) Reports Partnership with BARDA to Repurpose MN-166 (ibudilast) as Medical Countermeasure against Chlorine Gas-induced Lung Injury

Go back to Medicinova (MNOV) Reports Partnership with BARDA to Repurpose MN-166 (ibudilast) as Medical Countermeasure against Chlorine Gas-induced Lung Injury

MediciNova Announces Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury

March 9, 2021 4:00 PM EST

LA JOLLA, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has partnered with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, to repurpose MN-166 (ibudilast) as a potential medical countermeasure (MCM) against chlorine gas-induced lung damage such as acute respiratory distress syndrome (ARDS) and acute lung... More